| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

Show document Help

Title:A monocarbonyl curcuminoid derivative inhibits the activity of human glutathione transferase A4-4 and chemosensitizes glioblastoma cells to temozolomide
Authors:ID Tsouri, Steliana (Author)
ID Tselo, Evanthia (Author)
ID Premetis, Georgios E. (Author)
ID Furlan, Veronika (Author)
ID Pantiora, Panagiota D. (Author)
ID Mavroidi, Barbara (Author)
ID Matiadis, Dimitris (Author)
ID Pelecanou, Maria (Author)
ID Papageorgiou, Anastassios C. (Author)
ID Bren, Urban (Author)
ID Sagnou, Marina (Author)
ID Labrou, Nikolaos E. (Author)
Files:.pdf pharmaceuticals-17-00365.pdf (2,60 MB)
MD5: 883DA237082809904AC84E53C55D2B36
 
URL https://www.mdpi.com/1424-8247/17/3/365
 
Language:English
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FKKT - Faculty of Chemistry and Chemical Engineering
Abstract:Human glutathione transferase A4-4 (hGSTA4-4) displays high catalytic efficiency towards 4-hydroxyalkenals and other cytotoxic and mutagenic products of radical reactions and lipid peroxidation. Its role as a target for the chemosensitization of cancer cells has not been investigated so far. In this study, the inhibitory potency of twelve selected natural products and ten monocarbonyl curcumin derivatives against hGSTA4-4 was studied. Among natural products, ellagic acid turned out to be the strongest inhibitor with an IC50 value of 0.44 ± 0.01 µM. Kinetic analysis using glutathione (GSH) and 1-chloro-2,4-dinitrobenzene (CDNB) as variable substrates showed that ellagic acid behaved as a competitive inhibitor towards both GSH and CDNB, with Ki values of 0.39 ± 0.02 and 0.63 ± 0.03 µM, respectively. Among the curcumin derivatives studied, three proved to be the most potent inhibitors, in the order DM151 > DM101 > DM100, with IC50 values of 2.4 ± 0.1 µM, 12.7 ± 1.1 µM and 16.9 ± 0.4 µM, respectively. Further kinetic inhibition analysis of the most active derivative, DM151, demonstrated that this compound is a mixed inhibitor towards CDNB with inhibition constants of Ki = 4.1 ± 0.5 µM and Ki’ = 0.536 ± 0.034 µM, while it is a competitive inhibitor towards GSH with a Ki = 0.98 ± 0.11 µM. Molecular docking studies were performed to interpret the differences in binding of ellagic acid and curcumin derivatives to hGSTA4-4. The in silico measured docking scores were consistent with the obtained experimental data. Hydrogen bonds appear to be the main contributors to the specific binding of monocarbonyl curcumin derivatives, while π-π stacking interactions play a key role in the enzyme–ellagic acid interaction. In vitro cytotoxicity assessment of the worst (DM148) and the best (DM151) inhibitors was performed against glioblastoma cell lines U-251 MG and U-87 MG. The results revealed that DM151 displays considerably higher cytotoxicity against both glioblastoma cell lines, while the glioblastoma cytotoxicity of DM148 was very limited. Furthermore, low and non-toxic doses of DM151 sensitized U-251 MG cells to the first-line glioblastoma chemotherapeutic temozolomide (TMZ), allowing us to propose for the first time that hGSTA4-4 inhibitors may be attractive therapeutic partners for TMZ to optimize its clinical effect in glioblastoma chemotherapy.
Keywords:chemosensitization, chemoresistance, curcumin, glioblastoma, human glutathione transferase A4-4, ellagic acid, monocarbonyl curcumin derivatives, GST inhibition, temozolomide sensitization
Publication status:Published
Publication version:Version of Record
Submitted for review:19.02.2024
Article acceptance date:07.03.2024
Publication date:11.03.2024
Publisher:MDPI
Year of publishing:2024
Number of pages:18 str.
Numbering:let. 17, št. 3, št. članka 365
PID:20.500.12556/DKUM-90145 New window
UDC:577
ISSN on article:1424-8247
COBISS.SI-ID:189586435 New window
DOI:10.3390/ph17030365 New window
Copyright:© 2024 by the authors
Publication date in DKUM:23.08.2024
Views:173
Downloads:37
Metadata:XML DC-XML DC-RDF
Categories:Misc.
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share



Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Pharmaceuticals
Shortened title:Pharmaceuticals
Publisher:MDPI, Molecular Diversity Preservation International
ISSN:1424-8247
COBISS.SI-ID:517582617 New window

Document is financed by a project

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P2-0046
Name:Separacijski procesi in produktna tehnika

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P2-0438
Name:Optični kemijski/bio senzorski sistemi (OPTISENS)

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L2-3175
Name:Napredna ekstrakcija in formulacija funkcionalnih taninskih prahranskih dopolnil z blagodejnimi zdravstvenimi učinki

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-4398
Name:Kemijska karcinogeneza in nevrodegeneracija: Molekularni mehanizem vpliva mikrovalovnega sevanja

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:L2-4430
Name:Proizvodnja, izolacija in formulacija zdravju koristnih substanc iz Helichrysum Italicum za uporabo v kozmetični industriji

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-4498
Name:Multi-omska raziskava signalne poti NFkB pri multipli sklerozi

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J7-4638
Name:Načrtovanje selektivnih katalitskih postopkov pretvorbe CO2 v etanol – UliSess

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-4414
Name:ProBiS-Fold pristop za določanje vezavnih mest za celoten strukturni človeški proteom pri odkrivanju zdravil

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-4497
Name:Neinvazivni multi-omski biooznačevalci v podtipih imunskih celic za personalizirano zdravljenje otroške astme in molekularni mehanizmi neodzivnosti na inhalacijske kortikosteroide

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J4-4633
Name:Razumevanje mehanizmov in preprečevanje agregacije biofarmacevtskih proteinov

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:I0-E015
Name:Izvajanje mednarodnega infrastrukturnega projekta BBMRI

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-2471
Name:Kemijska karcinogeneza: Mehanistični vpogled

Funder:the Slovenian Ministry of Science and Education
Acronym:project grant NOO

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:kemijska občutljivost, kemijska obstojnost, kurkumin, inhibicija


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica